

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**ESPS manuscript NO:** 19687

**Title:** Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients

**Reviewer's code:** 03261461

**Reviewer's country:** Egypt

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2015-05-18 09:58

**Date reviewed:** 2015-05-30 00:59

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

Thanks for your submission entitled (Pharmaceutical management of Liver and Kidney Transplant Recipients against Recurrence of Hepatitis B and C Virus Infection) 1- This topic is one of the most important problems that the transplant physician faces and should be carefully managed. 2- The article is written in a good and simple language. 3- References are updated however in table 2 it will be very helpful if you add the HCV genotype that each drug cover I strongly recommend the publication of the article.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**ESPS manuscript NO:** 19687

**Title:** Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients

**Reviewer's code:** 02860895

**Reviewer's country:** Japan

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2015-05-18 09:58

**Date reviewed:** 2015-05-23 16:27

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

This is an editorial concerning liver/kidney transplantation for patients with viral hepatitis. There is no concern, but I'd like to make one request. I think it would be better for editorials to highlight articles of Baishideng Journals. If possible, please emphasize reference 15.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**ESPS manuscript NO:** 19687

**Title:** Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients

**Reviewer's code:** 03381964

**Reviewer's country:** India

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2015-05-18 09:58

**Date reviewed:** 2015-06-01 02:23

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

## COMMENTS TO AUTHORS

In this editorial, the authors have presented an interesting and useful brief on pharmaceutical management of liver/kidney transplant recipients. However, the article needs to be thoroughly checked for typographical/grammatical errors (the list below is not exhaustive): 1) Page 2, 1st word: ABSRACT. 2) Page 2: Full forms of HBIG and SVG should be mentioned in the abstract. 3) Page 2, line 5: ...for treatment na?ve kidney transplant recipients... 4) Page 2, lines 11-12: ...boosted the on treatment... 5) Page 3, Abbreviations: NAs: nucleos(t)ide analogue (should be "analogues"). 6) Page 4, 2nd para, lines 1-2: Potent with high-genetic...(HBV) decompensated cirrhosis in... 7) Page 4, 2nd para, line 7: ...usage requiring also additional... 8) Page 4, 3rd para, line 1: ...carried out from our team...(should be "by our team") 9) Page 5, top para: ...cost savings over HBIG-containing regimens...(the authors treatment therapy also contained HBIG). 10) Page 5, 2nd para, line 1:...prophylaxis needs be continued... 11) Page 5, 2nd para, lines 7-9:...limited antiviral options if HBV recurrence occurs such as... 12) Page 6, 2nd para, line 5: ...for treatment na?ve KT recipients... 13) Page 7, line 5 from bottom: ...encorporating... 14) Page 7, line 3 from bottom:...boosted the on



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

treatment and... 15) Page 8, lines 10-11: ....striking results impel European... 16) Page 9, lines 6-7: ...more pronounced on renal patients... 17) Page 9, line 8: ...might be proved valuable treatment... 18) Page 10: Concern expressed whether... 19) Table 2: 2nd row: No in patients with Child... 3rd row: Only in glomerular filtration... Page 14: NUC abbreviation used here while in article NA used (for the same words)

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**ESPS manuscript NO:** 19687

**Title:** Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients

**Reviewer's code:** 00182901

**Reviewer's country:** South Korea

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2015-05-18 09:58

**Date reviewed:** 2015-06-01 14:42

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

This "Editorial" is written nicely and concisely with up-to-date information of academic value and the reviewer hardly finds a point to be added in contents. Instead, the reviewer only points out a few details as follows. In Abstract, lines 3-4, the sentence "Preliminary data showed high efficacy of second generation direct oral antivirals in kidney transplant recipients as well." seems to mention about HCV. If so, it is better to place this sentence in the later part of Abstract. There are several grammatical and typo errors. For example, in Running Title, "Therapy of HBC and HCV after ...." should be changed to "Therapy of HBV and HCV after ....". In Abbreviations, "KT, kidney transplantation" should be changed to "KT, kidney transplantation". In page 4, line 8, "Potent with high-genetic barrier nucleos(t)ide analogues (NAs) should be...." should be changed to "Potent nucleos(t)ide analogues (NAs) with high-genetic barrier should be....". And, there are several more. Please check the entire manuscript carefully for grammatical and typo errors.